Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR) (ENDEAVOR)
ENDEAVOR Study: A Prospective Exploratory Study Describing the Course of Peripheral Neuropathy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin in Combination With Pembrolizumab and Supportive Neuridase
his prospective exploratory study aims to describe the course of peripheral neuropathy in patients with locally advanced or metastatic urothelial carcinoma treated with enfortumab vedotin in combination with pembrolizumab and receiving supportive Neuridase.
Peripheral neuropathy is a common adverse event associated with enfortumab vedotin and may negatively affect treatment tolerability, quality of life, and treatment continuation. Neuridase is a non-pharmacological supportive product intended to support peripheral nervous system function; however, its role in this clinical setting has not yet been established.
Participants enrolled in this single-arm study will receive standard-of-care treatment with enfortumab vedotin plus pembrolizumab, together with supportive Neuridase according to clinical practice. The study will prospectively assess neuropathy symptoms and severity using clinical evaluations and patient-reported outcome measures, including quality-of-life questionnaires, over the course of treatment.
The objective of the study is to explore neuropathy patterns and treatment tolerability in this patient population.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Lorenzo Antonuzzo, MD Phd, MD
- Telefonnummer: 055-5465353
- E-mail: lorenzo.antonuzzo@unifi.it
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
Age ≥18 years Histologically confirmed locally advanced or metastatic urothelial carcinoma Candidate for treatment with enfortumab vedotin in combination with pembrolizumab according to clinical practice Ability to provide written informed consent Adequate clinical conditions to participate in the study according to investigator judgment
Exclusion Criteria:
Pre-existing severe peripheral neuropathy that may interfere with study assessments Contraindications to enfortumab vedotin or pembrolizumab according to clinical practice Known hypersensitivity to components of Neuridase Pregnancy or breastfeeding Any medical, psychiatric, or social condition that, in the investigator's judgment, may interfere with study participation or interpretation of results
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: arm label
Participants with locally advanced or metastatic urothelial carcinoma will receive standard-of-care enfortumab vedotin in combination with pembrolizumab together with supportive Neuridase according to the study protocol.
Peripheral neuropathy symptoms, treatment tolerability, and patient-reported outcomes will be prospectively assessed during treatment.
|
Standard-of-care enfortumab vedotin administered according to approved clinical practice.
Standard-of-care pembrolizumab administered in combination with enfortumab vedotin according to approved clinical practice.
Supportive non-pharmacological product administered during treatment with enfortumab vedotin and pembrolizumab to prospectively explore peripheral neuropathy trajectory, tolerability, and patient-reported outcomes.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence and Severity of Peripheral Neuropathy
Tidsramme: From baseline to 6 months after treatment initiation
|
Incidence and severity of peripheral neuropathy will be prospectively assessed according to clinical evaluation and CTCAE criteria in patients receiving enfortumab vedotin plus pembrolizumab with supportive Neuridase.
|
From baseline to 6 months after treatment initiation
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i nervesystemet
- Neoplasmer
- Neuromuskulære sygdomme
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Karcinom
- Sygdomme i det perifere nervesystem
- Carcinom, overgangscelle
- Socioøkonomiske faktorer
- Befolkningsegenskaber
- Demografi
- Familieegenskaber
- Ægteskabelig status
- pembrolizumab
- Enfortumab Vedotin
- Enlig person
Andre undersøgelses-id-numre
- ENDEAVOR
- CE 30693_spe (Registry Identifier: CE Careggi)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Perifer nervesygdom
-
Mayo ClinicTilmelding efter invitationAnatomi af GSV for Rescue Peripheral IV AccessForenede Stater
-
Cairo UniversityAfsluttetPostoperativ smerte | Stellat ganglieblok | Magnesiumsulfat | Lokalbedøvelse | Modificeret radikal mastektomi | Pectoral nervEgypten
Kliniske forsøg med enfortumab vedotin (EV)
-
Generate BiomedicinesRekrutteringMetastatisk Urothelial Carcinom | Avanceret Urothelial CancerForenede Stater
-
Astellas Pharma Global Development, Inc.Seagen Inc.Godkendt til markedsføringLokalt avanceret eller metastatisk urothelial carcinom (UC)Forenede Stater
-
Guliz OzgunBritish Columbia Cancer AgencyIkke rekrutterer endnu
-
CSPC Megalith Biopharmaceutical Co.,Ltd.Ikke rekrutterer endnuAvanceret Urothelial Carcinom
-
National Cancer Center, JapanAstellas Pharma IncRekruttering
-
University of UtahAstellas Pharma IncAktiv, ikke rekrutterendeMetastatisk kastrationsresistent prostatakræftForenede Stater
-
Fox Chase Cancer CenterUnited States Department of DefenseRekrutteringMetastatisk Urothelial Carcinom | Uoperabelt Urothelial Carcinom | Avanceret Urothelial CarcinomForenede Stater
-
Merck Sharp & Dohme LLCRekrutteringBlærekræftIsrael, Forenede Stater, Sydkorea, Spanien, Frankrig, Holland, Chile, Det Forenede Kongerige
-
Astellas Pharma China, Inc.Seagen Inc.Afsluttet
-
Astellas Pharma Global Development, Inc.Seagen, a wholly owned subsidiary of PfizerAfsluttetKarcinom in situ | Urinblære neoplasmer | Ikke-muskel invasiv blærekræft | Carcinom overgangscelle | NMIBCForenede Stater, Spanien, Canada, Frankrig, Tyskland, Det Forenede Kongerige